FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Deka Petition Seeks Stair Wheelchair Reclassification

[ Price : $8.95]

Deka Research and Development Corp. petitions FDA to reclassify stair-climbing wheelchairs from Class 3 to Class 2 devices.

FzioMed Appeals CDRH PMA Denial of Oxiplex/SP Gel

[ Price : $8.95]

FzioMed seeks dispute panel resolution of a CDRH decision to deny approval for its PMA for Oxiplex/SP Gel for use in back surgery.

New OGD Procedure for Grouped CMC Supplements

[ Price : $8.95]

CDER releases a new policy procedure for handling reviews of grouped chemistry, manufacturing and controls supplements.

FDA Rejects Petition Seeking Lindane Ban

[ Price : $8.95]

FDA rejects a petition submitted by Natural Resources Defense Council that sought the market withdrawal of products containing lin...

FDA Accepts MAP Pharma Resubmission for Migraine Drug

[ Price : $8.95]

FDA accepts for review a MAP Pharmaceuticals NDA resubmission for Levadex (dihydroergotamine) inhalation aerosol for treating migr...

Guidance on Artificial Pancreas Device Systems

[ Price : $8.95]

Federal Register Notice: FDA releases a guidance, The Content of Investigational Device Exemption (IDE) and Premarket Approval (PM...

Guidance on HIV-Preventing Microbicides

[ Price : $8.95]

Federal Register Notice: FDA releases a draft guidance, Vaginal Microbicides: Development for the Prevention of HIV Infection.

FDA Posts Planned CDRH Guidances

[ Price : $8.95]

Federal Register Notice: FDA posts a Web site location for FY 2013 planned CDRH guidance documents.

Risk Communication Advisory Panel to Meet

[ Price : $8.95]

Federal Register Notice: FDAs Risk Communication Advisory Committee will meet 2/12 to discuss general risk communication factors. ...

FDA Green Light for Kidney Transplant Trial

[ Price : $8.95]

FDA gives Isotechnika Inc. permission to begin the first of two planned Phase 3 kidney transplant trials for its lead product cand...